Loading...

SAB Biotherapeutics

SAB Biotherapeutics, Inc.

How a South Dakota Bioscience Company is Transforming the Treatment of Disease

Sioux Falls-based SAB Biotherapeutics is a clinical-stage, BARDA-funded biopharmaceutical development company dedicated to developing and delivering natural, life-saving immunotherapies to address unmet needs in human health. Having developed some of the most advanced antibody science in the world, the company has created a premier immunotherapy approach–the DiversitAb™ platform–to produce human antibodies without using humans.

The proprietary platform leverages the power of polyclonal antibodies–the natural defense to disease– resulting in immunotherapies with increased safety, efficacy and tolerability. The DiversitAb platform also has the ability to rapidly produce large amounts of targeted human polyclonal antibodies (as quickly as 75 days). With its polyclonal nature, it can also address disease mutation and provides for a wide range of targets and applications.

The company is advancing a robust pipeline of products including commercial therapies for antibiotic resistance, severe hospitalized influenza, Type 1 diabetes and cancer along with emerging infectious disease targets including Ebola, MERS-CoV, Zika.

Company executives have cited the state’s strides over the last decade to develop the needed research infrastructure to support this critical industry.

One recent example: The University of South Dakota’s Discovery District, an 80-acre corporate and academic research park in Sioux Falls. SAB Biotherapeutics will serve as one of the anchor tenants of the $30.9 million project, which is scheduled to open in 2020.

Company Data

30+
Employees
$45+ million
awarded in government grants, contracts and in-kind since 2014
Only
Recognized by the World Health Organization as the only therapeutic platform technology capable of responding to pathogens with epidemic potential
12+
Produced therapeutics to more than a dozen targets (with 100% efficacy in vivo)
Phase I
Completed Phase I Clinical Trials for MERS-CoV and antibiotic resistant bacteria therapies
Partner
with prestigious organizations including: National Institutes of Health (NIH), Brigham and Women’s Hospital, Harvard Medical School, United States Research Institute of Infectious Diseases (USAMRIID), Sanford Health, National Institutes of Allergy and Infectious Disease (NIAID), Naval Medical Research Center (NMRC)

Contact Us

Natalie Likness

Media Relations Coordinator

Return to Top